SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline-Reference-Cited by-同舟云学术

SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline

Published:2021-01-05 Issue:8 Volume:223 Page:1334-1338
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Bolotin Shelly¹²³,Tran Vanessa¹³,Osman Selma¹,Brown Kevin A¹²,Buchan Sarah A¹²,Joh Eugene¹,Deeks Shelley L¹²,Allen Vanessa G¹³

Affiliation:

1. Public Health Ontario, Toronto, Ontario, Canada

2. Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

3. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

Abstract

Abstract We analyzed 21 676 residual specimens from Ontario, Canada collected March–August 2020 to investigate the effect of antibody decline on SARS-CoV-2 seroprevalence estimates. Testing specimens orthogonally using Abbott (anti-nucleocapsid) and Ortho (anti-spike) assays, seroprevalence estimates were 0.4%–1.4%, despite ongoing disease activity. The geometric mean concentration (GMC) of antibody-positive specimens decreased over time (P = .015), and GMC of antibody-negative specimens increased over time (P = .0018). Association between the 2 tests decreased each month (P < .001), suggesting anti-nucleocapsid antibody decline. Lowering Abbott antibody index cutoff from 1.4 to 0.7 resulted in a 16% increase in positive specimens.

Funder

Public Health Agency of Canada

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiaa796/36548882/jiaa796.pdf

Reference15 articles.

1. Humoral immune response to SARS-CoV-2 in Iceland;Gudbjartsson;N Engl J Med,2020

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering the Longevity and Levels of SARS-CoV-2 Antibodies in Children: A Year-Long Study Highlighting Clinical Phenotypes and Age-Related Variations;Pathogens;2024-07-26

2. SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali;International Journal of Infectious Diseases;2024-05

3. Evolution of seroprevalence to SARS‐CoV‐2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross‐sectional and longitudinal studies;Influenza and Other Respiratory Viruses;2023-08

4. A Mixture Model for Estimating SARS-CoV-2 Seroprevalence in Chennai, India;American Journal of Epidemiology;2023-04-21

5. Evaluation of anti-nucleocapsid level variation to assess SARS-CoV-2 seroprevalence in a vaccinated population;Infectious Diseases;2023-04-11